Nuclea
has developed a number of pan antibodies that greatly simplify and accelerate
the drug discovery processes in the tyrosine kinase (TK) disciplines. TK's
are the most popular targets for new drug discovery in the onocology arena
with significant advances in both genomics and proteomics. Thus, it makes
possible the rapid identification of proteins that play significant roles
in disease, many of which will become novel drug targets or diagnostic markers.
more>>
Nuclea has developed a number of pan antibodies that greatly simplify and accelerate the drug discovery processes in the MAPKAP Kinase (TK) disciplines. TK's are the most popular targets for new drug discovery in the oncology arena with significant advances in both genomics and proteomics. Thus, it makes possible the rapid identification of proteins that play significant roles in disease, many of which will become novel drug targets or diagnostic markers. more>>
Nuclea has developed a number of pan antibodies that greatly simplify and accelerate the drug discovery processes in the PI3 Kinase (TK) disciplines. TK's are the most popular targets for new drug discovery in the oncology arena with significant advances in both genomics and proteomics. Thus, it makes possible the rapid identification of proteins that play significant roles in disease, many of which will become novel drug targets or diagnostic markers. more>>
Nuclea Tissue Microarray Technology
Nuclea Biomarkers, LLC uses proprietary instrumentation and technology to develop and construct tissue microarrays from human and non-human samples for use in the discovery of new gene and protein signatures. We also develop comprehensive Protein Expression Databases that are used primarily for in-house development of intellectual property.
Nuclea has developed a proprietary technology which helps to identify protein or peptide biomarkers of disease directly from whole tissue samples, a process that is still highly valuable despite significant advances in both genomics and proteomics. By combining proteomics methodologies with high-throughout genomic analysis, this technology eliminates the need for protein purification and greatly increases efficiency. Thus, it makes possible the rapid identification of proteins that play significant roles in disease, many of which will become novel drug targets or diagnostic markers. more>>
SPRING 2008
DFCI Impact Spring 2008 Nuclea Biomarkers Drives Study into the Molecular Pathology of Cancer
04/10/08
NUCLEA BIOMARKERS ANNOUNCES THAT IT HAS RECEIVED A U.S. PATENT ON "KINASE PEPTIDES AND ANTIBODIES"
7/15/07
NUCLEA BIOMARKERS RENEWS RESEARCH COLLABORATION WITH DANA FARBER CANCER INSTITUTE
06/05/06
Nuclea Biomarkers Announces it has Received a Notice of Allowance for U.S. Design Patent
08/10/05
Nuclea Biomarkers Establishes Research Collaboration with Dana Farber Cancer Institute
03/08/06 - Berkshire Economic Development Corporation
Biotech firm on its way
Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to improve greatly the efficiency of drug discovery research.
Using the Company's extensive libraries of genetic, molecular, and outcomes data and data-mining services, research professionals in pharmaceutical and life sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.
